Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UNDISCLOSED-3
- Development stage
- Preclinical
- Lead developer
- Macomics
- Modality
- Antibody-Based Therapeutics, Small Molecules
01
Overview
UNDISCLOSED-3 is a preclinical therapeutic program being developed by Macomics, focusing on the modulation of macrophage-driven fibrotic processes. The program targets a specific pathway involved in macrophage-mediated extracellular matrix (ECM) degradation and the subsequent activation of myofibroblasts. By inhibiting these mechanisms, the drug aims to halt or reverse the progression of fibrotic diseases such as Idiopathic Pulmonary Fibrosis (IPF) and Non-Alcoholic Steatohepatitis (NASH). As of early 2024, the program is in the discovery phase, leveraging Macomics' expertise in macrophage biology to develop either antibody or small molecule interventions.
Beyond the preview
Go deeper on UNDISCLOSED-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UNDISCLOSED-3.